Disagree with your analysis, when considering the discrepancy between US and AUS vehicles.
When reviewing the AUS data alone, the primary endpoint data is statistically significant for inflammatory lesions.
IF there had been no discrepancy, your analysis would stand.
Unfortunately, the data is the data and BOT cannot discredit the US results (at this stage anyway), however they have clearly undertaken a root cause analysis and put a plan in motion to resolve for phase 3.
Cheers,
Sven
Disagree with your analysis, when considering the discrepancy...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
-0.110(35.5%) |
Mkt cap ! $367.7M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 17.5¢ | $10.39M | 50.80M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 641473 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 672556 | 26 |
View Market Depth
| Last trade - 10.58am 08/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |